<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048502</url>
  </required_header>
  <id_info>
    <org_study_id>810598</org_study_id>
    <secondary_id>P50HL083799</secondary_id>
    <nct_id>NCT01048502</nct_id>
  </id_info>
  <brief_title>Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia</brief_title>
  <acronym>FFAME</acronym>
  <official_title>Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the anti-inflammatory benefits of two
      prescription medicines that are currently used to help people with cholesterol problems.

      Fish oil, from eating certain kinds of fish and from supplement pills, has been used to help
      control cholesterol and reduce inflammation (the body's response to injury or sickness).
      Lovaza® is the brand name for prescription strength fish oil pills. In this study, we will be
      looking at how Lovaza® works to help reduce inflammation in healthy volunteers.

      Tricor® is the brand name for prescription fenofibrate pills. Fenofibrate is a prescription
      medicine that many doctors give to people with high triglyceride (fat in the blood) levels.
      In this study, we will be looking at how Tricor® works to help reduce inflammation in healthy
      volunteers.

      Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living)
      that can cause many of the effects similar to bacterial infections in humans. However, it can
      be administered in very small amounts to produce a mild immune response much the same as a
      'flu' like illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of
      fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which
      lasts up to 6-8 hours. In addition to the flu like symptoms, the response causes temporary
      changes in cholesterol, triglycerides and blood sugar. Different people respond differently
      to LPS. We are using LPS in this study to bring on a temporary inflammatory response in the
      body and to compare the responses of people who receive Lovaza® or Tricor® to the responses
      of people who receive a placebo (pill that does not contain medicine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS).</measure>
    <time_frame>randomization and 8 weeks post</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Inflammatory Parameter (Plasma TNF-α Levels) After Treatment With Fenofibrate or Placebo.</measure>
    <time_frame>baseline and 6-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Fenofibrate (Tricor) (145 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovaza (900 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovaza (3,600 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate (Tricor) tablets</intervention_name>
    <description>One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks</description>
    <arm_group_label>Fenofibrate (Tricor) (145 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
    <arm_group_label>Lovaza (900 mg/day)</arm_group_label>
    <arm_group_label>Lovaza (3,600 mg/day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant/lactating women between the ages of 18 and 45.

          -  Body Mass Index (BMI) ≥18 and ≤30

          -  Participants who are able to give written informed consent and willing to comply with
             all study-related procedures.

        Exclusion Criteria:

          -  Known clinically manifest atherosclerotic cardiovascular disease, including coronary
             disease, cerebrovascular disease, or peripheral vascular disease

          -  History of diabetes mellitus

          -  Fasting glucose &gt;126mg/dL at screening

          -  History of a non-skin malignancy within the previous 5 years

          -  Renal insufficiency as defined by creatinine outside of lab defined normal range or
             eGFR &lt;60 ml/Kg/min at Screening Visit

          -  History of liver disease or abnormal Liver Function Tests (LFTs) (aspartate
             aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase,
             gamma-glutamyl transpeptidase (GGT) &gt; 1.5x upper limit of normal (ULN); bilirubin &gt; 2x
             ULN) at Screening Visit

          -  Men who are unwilling to limit alcohol consumption to &lt; 14 alcoholic drinks per week
             or &lt; 4 alcoholic drinks per occasion (American Medical Association/National Institute
             on Alcohol Abuse and Alcoholism (AMA / NIAAA) criteria for &quot;at risk&quot; usage levels)
             while participating in the study

          -  Women who are unwilling to limit alcohol consumption to &lt; 7 alcoholic drinks per week
             or &lt; 3 alcoholic drinks per occasion (AMA / NIAAA criteria for &quot;at risk&quot; usage levels)
             while participating in the study

          -  Total white blood cell count less than or equal to 3.0 THO/uL

          -  Hemoglobin less than 11.0 g/dL

          -  Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory
             condition or minor active infection

          -  Self-reported history of HIV positive

          -  First degree family history of premature cardiovascular disease event (father or
             brother if diagnosed at before 55 years of age; mother or sister if diagnosed before
             65 years of age)

          -  Patients who have undergone any organ transplant

          -  Individuals who currently use tobacco products or have done so in the previous 30 days

          -  Treatment with aspirin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs),
             cyclooxygenase-2 (COX-2) inhibitors, steroids or any immunomodulatory therapy 2 weeks
             prior to the Screening Visit

          -  Treatment with statins, fibrates or niacin 4 weeks prior to the Screening Visit.

          -  Current daily use of Vitamin C &gt; 1000 mg, Beta carotene &gt; 1000 IU, vitamin A &gt; 5000
             IU, vitamin E &gt; 400 IU, and selenium &gt; 200 mcg

          -  Participants who are unwilling to eliminate omega-3 fatty acid (eicosapentaenoic acid
             (EPA) + docosahexaenoic acid (DHA)) supplements and/or fortified food, or have their
             usual intake of high omega-3 fish (tuna and other non-fried fish) be &gt; 3 to 4 servings
             per month as assessed by a simple screening questionnaire

          -  Positive urine pregnancy test result.

          -  Participation in another clinical trial within the previous 6 weeks prior to the
             Screening Visit.

          -  Poorly controlled blood pressure (BP &gt; 160/110) or on any anti-hypertensive
             medications.

          -  A diagnosis of metabolic syndrome using updated 2004 National Cholesterol Education
             Program Adult Treatment Panel III (NCEP ATPIII) criteria.

          -  Any medical condition or abnormal laboratory value that is judged clinically
             significant by an investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muredach P Reilly, MB, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2016</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>100 subjects were enrolled; 80 completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fenofibrate (Tricor) (145 mg/Day)</title>
          <description>Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
Fenofibrate (Tricor) tablets: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 Fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
Placebo: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Lovaza (900 mg/Day)</title>
          <description>Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo – supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Lovaza (3,600 mg/Day)</title>
          <description>Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fenofibrate (Tricor) (145 mg/Day)</title>
          <description>Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
Fenofibrate (Tricor)tablets: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 Fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
Placebo: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Lovaza (900 mg/Day)</title>
          <description>Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo – supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Lovaza (3,600 mg/Day)</title>
          <description>Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.58" lower_limit="21" upper_limit="43"/>
                    <measurement group_id="B2" value="25.96" lower_limit="18" upper_limit="43"/>
                    <measurement group_id="B3" value="26.68" lower_limit="18" upper_limit="42"/>
                    <measurement group_id="B4" value="24.68" lower_limit="19" upper_limit="36"/>
                    <measurement group_id="B5" value="25.75" lower_limit="18" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS).</title>
        <time_frame>randomization and 8 weeks post</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 Fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
Placebo: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lovaza (900 mg/Day)</title>
            <description>Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo – supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Lovaza (3,600 mg/Day)</title>
            <description>Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS).</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-α at randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.8" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.26" lower_limit="0.72" upper_limit="1.76"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.76" upper_limit="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α 8 weeks post randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.64" upper_limit="1.84"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.78" upper_limit="1.76"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.64" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Inflammatory Parameter (Plasma TNF-α Levels) After Treatment With Fenofibrate or Placebo.</title>
        <time_frame>baseline and 6-8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate (Tricor) (145 mg/Day)</title>
            <description>Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
Fenofibrate (Tricor)tablets: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 Fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
Placebo: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Inflammatory Parameter (Plasma TNF-α Levels) After Treatment With Fenofibrate or Placebo.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-α at randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α 6-8 weeks post randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tricor (145 mg/Day)</title>
          <description>Participants will be given 1 Tricor 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
Fenofibrate tablets: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will be given 5 placebo pills (4 fish oil placebo and 1 Fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
Placebo: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Lovaza (900 mg/Day)</title>
          <description>Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo – supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Lovaza (3,600 mg/Day)</title>
          <description>Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
Lovaza: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>&gt; 2g drop in Hgb from baseline</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cold/allergy symptoms</sub_title>
                <description>Subjects reported having illnesses that were unrelated to study but that occurred during participation.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muredach Reilly</name_or_title>
      <organization>UPenn</organization>
      <phone>215-573-1214</phone>
      <email>muredach@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

